

Appendix 1. Crude and Adjusted Prevalences of Opioid Pharmacotherapy Utilization Among Medicaid-Enrolled Pregnant Women With OUD, 2009-2015*

Year	Crude prevalence, % (95% CI)			Adjusted prevalence, % (95% CI)		
	None observed	Methadone	Buprenorphine	None observed	Methadone	Buprenorphine
2009	53.2 (50.6-55.9)	31.6 (29.2-34.1)	15.1 (13.2-17.0)	52.6 (50.1-55.1)	31.6 (29.3-33.9)	15.8 (13.9-17.8)
2010	43.6 (41.1-46.1)	34.7 (32.3-37.1)	21.7 (19.6-23.8)	43.1 (40.7-45.5)	35.2 (32.9-37.5)	21.7 (19.7-23.8)
2011	42.0 (39.7-44.4)	32.8 (30.5-35)	25.2 (23.1-27.3)	42.0 (39.8-44.3)	33.0 (30.9-35.1)	25.0 (23.0-27.0)
2012	42.5 (40.2-44.7)	29.0 (26.9-31.1)	28.5 (26.5-30.6)	42.8 (40.7-45)	28.7 (26.8-30.6)	28.5 (26.5-30.5)
2013	43.6 (41.5-45.7)	27.1 (25.2-29.0)	29.2 (27.3-31.2)	43.8 (41.8-45.8)	27.4 (25.6-29.2)	28.9 (27.0-30.7)
2014	42.5 (40.4-44.5)	24.2 (22.5-26.0)	33.3 (31.4-35.3)	42.8 (40.8-44.8)	24.0 (22.3-25.6)	33.2 (31.3-35.1)
2015	43.9 (41.6-46.2)	25.1 (23.1-27.1)	31.0 (28.9-33.1)	43.9 (41.8-46.1)	25.2 (23.3-27.1)	30.9 (28.8-33.0)

*Adjusted prevalences derived from multivariable negative binomial regression model controlling for: year of delivery, age, race, ethnicity, Medicaid region, medical co-morbidities including psychiatric disorder, HCV and HIV infection and substance use history including tobacco, alcohol and polysubstance use.

Krans EE, Kim JY, James AE, Kelley D, Jarlenski MP. Medication-assisted treatment utilization among pregnant women with opioid use disorder. *Obstet Gynecol* 2019; 133.

The authors provided this information as a supplement to their article.

©2019 American College of Obstetricians and Gynecologists.

Appendix 2. Crude and Adjusted Counts of Behavioral Health Counseling Utilization by Opioid Pharmacotherapy Type Among Medicaid-Enrolled Pregnant Women With OUD, 2009-2015*

Year	Crude visit counts, N (95% CI)			Adjusted visit counts, N (95% CI) ^a		
	None observed	Methadone	Buprenorphine	None observed	Methadone	Buprenorphine
2009	3.3 (2.9-3.8)	6.2 (5.2-7.2)	3.9 (3.3-4.6)	3.6 (2.9-4.3)	5.7 (4.3-7.1)	3.1 (2.0-4.2)
2010	2.9 (2.5-3.3)	5.4 (4.5-6.2)	3.4 (2.9-3.9)	3.0 (2.4-3.7)	4.1 (3.2-5.0)	5.4 (3.8-6.9)
2011	3.0 (2.6-3.4)	5.6 (4.8-6.4)	3.5 (3.0-4.1)	3.1 (2.5-3.7)	4.4 (3.4-5.3)	4.8 (3.6-6.0)
2012	3.2 (2.7-3.6)	5.9 (5.0-6.8)	3.7 (3.2-4.3)	3.5 (2.8-4.1)	5.0 (3.9-6.2)	4.5 (3.5-5.6)
2013	2.7 (2.4-3.1)	5.1 (4.4- 5.7)	3.2 (2.8-3.6)	3.0 (2.5-3.5)	5.1 (4.0-6.2)	3.3 (2.6-4.0)
2014	3.1 (2.7-3.5)	5.9 (5.1-6.6)	3.7 (3.2-4.2)	3.1 (2.6-3.6)	5.6 (4.4-6.8)	3.5 (2.8-4.2)
2015	3.6 (3.1-4.1)	6.8 (5.8-7.7)	4.3 (3.7-4.9)	4.0 (3.3-4.7)	6.4 (4.9-7.9)	3.4 (2.6-4.1)

*Adjusted counts derived from multivariable negative binomial regression model controlling for: year of delivery, age, race, ethnicity, Medicaid region, medical co-morbidities including psychiatric disorder, HCV and HIV infection and substance use history including tobacco, alcohol and polysubstance use.

Krans EE, Kim JY, James AE, Kelley D, Jarlenski MP. Medication-assisted treatment utilization among pregnant women with opioid use disorder. *Obstet Gynecol* 2019; 133.

The authors provided this information as a supplement to their article.

©2019 American College of Obstetricians and Gynecologists.